Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2010 Oct 12;17(3):330–340. doi: 10.1016/j.bbmt.2010.09.020

Figure 6.

Figure 6

Rechallenge of surviving GM-MMB3.19 vaccinated mice. Surviving GM-MMB3.19 vaccinated (i.p. or s.c.) mice were rechallenge with 5×106 MMB3.19 cells (i.p.) at ≥ 12 weeks post-BMT, or were used as donors for adoptive transfer of 2×106 ATBM cells along with 4-5×106 DL. For control purposes, their ATBM counterparts were also challenged with an equal dosage of tumor cells or were used as donors in adoptive transfer experiments. Adoptive transfer data were pooled from 2 different experiments of 10 mice per group. Re-challenge data were pooled from 4-5 different experiments consisting of 3-5 mice per group.